
“GLP-1 Tracker”

“Works with any GLP-1”

“Meet Capy, your GLP-1 companion”

“Eat enough, not less”

“One plan, built for you”

“Stay on schedule”

“Log food in seconds”

“Track change beyond the scale”

“See how far you've come”

“#1 GLP-1 companion app”
A closer look at the screenshots

The dashboard names Zepbound and shows a dose estimate.

A checklist lists medication brands and additional options.

A pixel-art capybara appears in a chat interface.

The screen presents nutrition guidance for GLP-1 use.

A weight-goal line accompanies a symptom-related plan note.

A shot-day notification sits above a Take Shot checklist.

Protein and fiber tags overlay a food camera view.

A progress selfie appears above a strip of earlier photos.

A weight trend has an Almost there annotation.

User headshots accompany weight figures and medication names.
About this app
MeAgain is the GLP-1 tracker app for shots and pills — the simple place to track every dose and everything in between. Use MeAgain for Zepbound®, Wegovy® injection or pill, Ozempic®, Mounjaro®, Foundayo®, semaglutide, tirzepatide, oral GLP-1s and weekly injection routines. GLP-1 tracking should not feel like another job. There is shot day, pill timing, food noise, low appetite, protein and water goals, side effects, weight stalls, progress photos and dose-day patterns. MeAgain brings the routine together with less mental load, less guesswork and one place to stay on top of what matters. TRACK SHOT DAYS, PILLS AND DOSES • Log GLP-1 shots and oral pill routines • Track dose timing, injection sites and shot days • Set shot reminders and pill reminders • See medication-level context between doses • Keep first-month GLP-1 tracking more organized FOOD, PROTEIN, FIBER AND WATER • Log food with photo, barcode and search • Track protein, fiber and water when appetite is low • Keep meals connected to symptoms, weight and dose days • Sync movement and health data with Apple Health SIDE-EFFECT TRACKER AND JOURNAL • Log nausea, constipation, reflux, fatigue and custom symptoms • Track timing, severity and notes • See symptoms beside food, water, weight and dose context • Keep clearer notes to discuss with your healthcare provider PROGRESS BEYOND THE SCALE • Weight tracker and trend view • Progress photos and Journey Cards • Daily timeline for food, shots, pills, symptoms and movement • Widgets, including Capy, to keep your routine visible WHY MEAGAIN Generic food apps focus on calories. Medication reminder apps focus on alarms. MeAgain is built for the GLP-1 routine itself: dose, site, food, protein, fiber, water, side effects, weight, photos and consistency together. MeAgain is for tracking and education only. It does not provide medical advice, diagnose conditions, treat side effects, recommend dose changes or replace your healthcare provider. Always talk with your healthcare provider about medication decisions, side effects or health concerns. Some features require a subscription. Privacy Policy: https://meagain.com/privacy Terms: https://meagain.com/terms Support: https://meagain.com/support
Headlines in this set
10 screenshots · 10 with a headline
“GLP-1 Tracker”
The category label identifies GLP-1 users as the audience.
“Works with any GLP-1”
Any promises broad medication support without listing limits.
“Meet Capy, your GLP-1 companion”
Naming Capy gives the tracking assistant a character identity.
“Eat enough, not less”
Enough, not less challenges the usual calorie-reduction message.
“One plan, built for you”
One plan and built for you stress a single personal plan.
“Stay on schedule”
Schedule points to the recurring medication routine.
“Log food in seconds”
In seconds is a speed claim that the still image cannot measure.
“Track change beyond the scale”
Beyond the scale expands progress to visible changes.
“See how far you've come”
How far you've come frames the chart as a record of past effort.
“#1 GLP-1 companion app”
The number-one claim asserts rank without a basis in the headline.
How Health & Fitness sets are usually built
Most Health & Fitness apps feature-per-slide, with text-top-device-bottom (65% of sets, 76% of screens).